McKesson Corporation Announces Fourth-Quarter Fiscal 2023 Earnings Release Date
IRVING, Texas, March 27, 2022 —McKesson Corporation (NYSE: MCK) will release its fourth-quarter and full-year fiscal 2023 financial results after market close on Monday, May 8, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review i... (Source: McKesson News)
Source: McKesson News - March 27, 2023 Category: Information Technology Source Type: news
McKesson Medical-Surgical Government Solutions Awarded Federal Supply Schedule Medical Equipment and Supply Contract
RICHMOND, VA, March 20, 2023 —McKess on Medical-Surgical Government Solutions LLC, a Richmond, Va.-based leading distributor of medical supplies and healthcare solutions, is proud to announce that it has been awarded a five-year U.S. Department of Veterans Affairs (VA) Federal Supply Schedule (FSS) 6... (Source: McKesson News)
Source: McKesson News - March 20, 2023 Category: Information Technology Source Type: news
McKesson Designated by CMS as 2023 Qualified Clinical Data Registry
IRVING, Texas, Feb. 15, 2023 —For the seventh consecutive year, McKesson has received approval from The Centers for Medicare& Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System (MIPS) as a Qualified Clinical Data Registry (QCDR). The designation enables iKnowMed ℠ elec... (Source: McKesson News)
Source: McKesson News - February 15, 2023 Category: Information Technology Source Type: news
JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson
CARY, N.C., Feb. 14, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Lilly as a specialty pharmacy provider for JAYPIRCATM (pirtobrutinib) for the treatment of adult patients with relapsed or refractory mantle cell l... (Source: McKesson News)
Source: McKesson News - February 14, 2023 Category: Information Technology Source Type: news
ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Feb. 10, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Stemline Therapeutics Inc., as a limited distribution network specialty pharmacy provider for ORSERDU™ (elacestrant). (Source: McKesson News)
Source: McKesson News - February 10, 2023 Category: Information Technology Source Type: news
McKesson Corporation Reports Fiscal 2023 Third-Quarter Results and Raises Full-Year Guidance
Third-Quarter Highlights: (Source: McKesson News)
Source: McKesson News - February 1, 2023 Category: Information Technology Source Type: news
McKesson Declares Quarterly Dividend
IRVING, Texas, January 26, 2023 —The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 54 cents per share of common stock. The dividend will be payable on April 3, 2023, to stockholders of record on March 1, 2023. (Source: McKesson News)
Source: McKesson News - January 26, 2023 Category: Information Technology Source Type: news
McKesson Receives Approval of Its Near-term Climate Change Targets by the Globally Recognized Science Based Targets Initiative
IRVING, Texas, Jan. 23 2023 — McKesson Corporation today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term climate change targets that contribute to reducing its Greenhouse Gas (GHG) emissions. McKesson joins more than 2,000 companies c... (Source: McKesson News)
Source: McKesson News - January 23, 2023 Category: Information Technology Source Type: news
The US Oncology Network Continues its Rapid Growth into New Communities, Adding Epic Care and Nexus Health
IRVING, Texas, Jan. 17, 2023 — The US Oncology Network (The Network), the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its footprint into local communities with the addition of two large multidisciplinary practices, Epic C... (Source: McKesson News)
Source: McKesson News - January 17, 2023 Category: Information Technology Source Type: news
McKesson Corporation Announces Third-Quarter Fiscal 2023 Earnings Release Date
IRVING, Texas, December 28, 2022 —McKesson Corporation (NYSE: MCK) will release its third-quarter fiscal 2023 financial results after market close on Wednesday, February 1, 2023. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its f... (Source: McKesson News)
Source: McKesson News - December 28, 2022 Category: Information Technology Source Type: news
FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Aadi Bioscience as a specialty pharmacy provider for FYARROTM (sirolimus protein-bound particles for injectable suspension) (albumin-bound). FYARRO was ... (Source: McKesson News)
Source: McKesson News - December 22, 2022 Category: Information Technology Source Type: news
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network for REZLIDHIATM (olutasidenib), which is indicated for... (Source: McKesson News)
Source: McKesson News - December 19, 2022 Category: Information Technology Source Type: news
KRAZATI ® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two specialty pharmacies in a limited distribution network for KRAZATI® (adagrasib), which is indicated for the treatmen... (Source: McKesson News)
Source: McKesson News - December 14, 2022 Category: Information Technology Source Type: news
ELAHERE ™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson
CARY, N.C., Dec. 12, 2022 — Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs), as the sole specialty pharmacy provider for ELAHERE™ (mirvet... (Source: McKesson News)
Source: McKesson News - December 12, 2022 Category: Information Technology Source Type: news
McKesson Foundation Awards $4.1 Million to Pharmacy Schools to Help Close Diversity Gap and Improve Health Outcomes
IRVING, TX – Nov. 7, 2022—The McKesson Foundation is on a mission to help increase diversity of the pharmacy workforce and improve overall health outcomes for vulnerable populations by donating more than $4.1 million to pharmacy schools at Hampton University, University of Michigan, University of Mi... (Source: McKesson News)
Source: McKesson News - November 7, 2022 Category: Information Technology Source Type: news
